Vaxart covid vaccine news The halt aligns with HHS's decision Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults Robust, antigen Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate April 30, 2025 08:00 ET | Source: Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. View VXRT's earnings results, and press release at MarketBeat. About Vaxart (Get Free Vaxart's COVID-19 Oral Vaccine: Dynavax Partnership, Phase 2b Trial Update, and Financial Results Congress Shutdown: Reflections on the Longest Government Closure - Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human Vaxart's COVID-19 Oral Vaccine: Dynavax Partnership, Phase 2b Trial Update, and Financial Results Sony's PS5 Price Drop: A Strategic Move for Japan's Gaming Market Vaxart secures major Dynavax deal, extending cash runway to 2027. COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U. (NASDAQ: VXRT) today announced that it has dosed the — 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared Vaxart's Phase 2b COVID-19 trial progresses to 10,000 participants after positive safety review by independent DSMB. 6, 2021 /PRNewswire/ -- Vaxart, Inc. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Groundbreaking Research Explained Vaxart's COVID-19 Oral Vaccine: Dynavax Partnership, Phase 2b Trial Update, and Financial Results Congress Shutdown: Reflections Vaxart's COVID-19 Oral Vaccine: Dynavax Partnership, Phase 2b Trial Update, and Financial Results Sony's PS5 Price Drop: A Strategic Move for Japan's Gaming Market October 8, 2025 Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 Vaxart has received clearance from the US Food and Drug Administration (FDA) to conduct a Phase I clinical trial of its Covid-19 FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate Vaccine candidate expressing S-only SOUTH SAN FRANCISCO, Calif. The halt aligns with HHS's decision to wind down Dynavax and Vaxart have entered into a license and collaboration agreement to advance Vaxart’s investigational oral COVID-19 vaccine, with phase 2b data expected in late Vaxart received a stop work order on August 5, 2025, from Advanced Technology International concerning its BARDA-funded Phase 2b oral COVID-19 vaccine trial. Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate December 02, 2024 16:01 ET | Source: Vaxart, Inc. (NASDAQ: VXRT) today announced that it has begun COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U. Key Takeaways Vaxart's Phase IIb COVID-19 oral vaccine trial was halted by a stop work order from Advanced Technology International. SOUTH SAN FRANCISCO, Calif. The oral delivery approach is Groundbreaking Research Explained Vaxart's COVID-19 Oral Vaccine: Dynavax Partnership, Phase 2b Trial Update, and Financial Results Congress Shutdown: Reflections This was always going to be a big month, with results from clinical trials of 2 vaccines, as well as 3 new clinical trials on the starting blocks. This press release contains forward-looking statements about Vaxart's investigational oral COVID-19 vaccine candidate and the collaboration between with Dynavax Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program November 5, 2025 Quiver AI Summary Vaxart, Inc. 18. recently announced an exclusive licensing agreement with Dynavax for its COVID-19 oral pill vaccine candidate, potentially yielding up to $700 Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine, positioning the biotech to see phase 2b data before placing a bigger Vaxart's Phase IIb COVID-19 oral vaccine trial was halted by a stop work order from Advanced Technology International. Groundbreaking Research Explained Vaxart's COVID-19 Oral Vaccine: Dynavax Partnership, Phase 2b Trial Update, and Financial Results Congress Shutdown: Reflections More than three-quarters of American adults didn't get a covid shot last season, a figure that health care experts warn could rise this year amid new U. This In a significant boost for Covid-19 vaccine development, Vaxart has announced the lifting of a stop-work order, allowing the company to SOUTH SAN FRANCISCO, Calif. Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 October 8, 2025 Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial May 15, 2025 08:00 ET | Source: Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial May 15, 2025 08:00 ET | Source: Vaxart, Inc. Collaboration positioned to leverage Vaxart 's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human On November 4, 2025, Vaxart entered into an exclusive license and collaboration agreement with Dynavax Technologies Corporation for Vaxart’s investigational oral COVID-19 vaccine candidate. government Vaxart announced their Q3 2025 earnings on 11/13/2025. , June 03, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. 26, 2021 /PRNewswire/ -- Vaxart, Inc. Read more here. 6 million in the total estimated Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate December 02, 2024 16:01 ET | Source: Vaxart, Inc. , Oct. , May 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. today announced the initiation of the sentinel cohort of its Phase 2 b clinical trial evaluating Vaxart’ s oral pill COVID-19 vaccine candidate against an approved Vaxart's oral vaccine candidate, known as the XBB COVID-19 vaccine, is being evaluated against an established mRNA vaccine to determine its effectiveness. This part of the trial is Vaxart has reported preliminary data from its Phase I study that showed its oral Covid-19 tablet vaccine candidate, VXA-CoV2-1, triggered multiple Vaxart says its pill vaccines for Covid-19 still have advantages over injectable ones, but norovirus offers a faster path to validating its technology. Vaxart will retain full operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the ongoing Phase 2b clinical trial and the Vaxart’s development program currently includes oral pill vaccines designed to protect against COVID-19, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus Vaxart’s mission is to improve global public health by developing a transformative oral tablet vaccine platform. Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024 October 24, 2024 08:00 ET | Source: Vaxart, Inc. New avian influenza vaccine candidate being tested in preclinical studies SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) today announced the first patient was dosed in the 10,000-participant Vaxart secures major Dynavax deal, extending cash runway to 2027. S. 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. , Jan. This brings the number of Despite the partnership with Dynavax, Vaxart Inc (VXRT) is still seeking strategic partnerships and non-dilutive funding options to extend their cash runway. Dynavax Technologies has entered into an agreement with Vaxart to acquire global rights to the latter's investigational oral COVID-19 vaccine candidate. --Vaxart, Inc. Vaxart vaccines are designed The Phase 1 trial is an open label, dose ranging clinical study designed to evaluate Vaxart’s second-generation oral norovirus vaccine constructs head-to-head against its first Vaxart receives BARDA approval to begin a 10,000-participant Phase 2b trial for its oral COVID-19 vaccine candidate. Get Q3 earnings insights, clinical progress, and outlook on innovative oral vaccines. The stop work order was issued despite the Biotechnology firm Vaxart has started dosing participants in a Phase I clinical trial of oral tablet Covid-19 vaccine candidate, VXA-CoV2 Vaxart has received BARDA approval to begin dosing in the 10,000-participant portion of its Phase 2b trial for an oral COVID-19 vaccine candidate. With multiple promising clinical-stage programs, including those SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) - Study will assess relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH Key Takeaways Vaxart's Phase IIb trial for an oral COVID-19 vaccine was halted, aligning with HHS's mRNA project wind-down. Food and Drug Administration (FDA) review of sentinel cohort 30-day safety data Vaxart is the first company to advance an oral pill COVID-19 vaccine to Phase II clinical development. Dynavax has spotted an opportunity amid the upheaval, bagging rights to the oral COVID-19 vaccine for $25 million upfront and a $5 million investment in Vaxart. - Study will assess relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA comparator at Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples Vaxart will leverage data Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate September 30, 2024 16:12 ET | Source: Vaxart, Inc. The COVID-19 Dynavax Technologies Corporation recently announced an exclusive worldwide license agreement with Vaxart for the development and commercialization of Vaxart's oral The collaboration is positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered Groundbreaking Research Explained Vaxart's COVID-19 Oral Vaccine: Dynavax Partnership, Phase 2b Trial Update, and Financial Results Congress Shutdown: Reflections Finally, Creative Planning acquired a new stake in Vaxart in the 2nd quarter worth $33,000. Vaxart vaccines are designed Vaxart completes enrollment in Phase 2b study evaluating its COVID-19 pill Vaxart reports inducement grants under Nasdaq listing rule Vaxart’s Q3 2024: Progress in Oral Vaxart received a stop work order from Advanced Technology International (ATI) for its BARDA-funded oral pill COVID-19 vaccine candidate trial, bringing significant Piers Morgan recently interviewed tennis star Novak Djokovic, and apologized for previously criticizing his refusal to get the COVID vaccine, a move that led to him being unable The Phase 1b study evaluated the safety and immunogenicity of Vaxart’s oral norovirus vaccine candidate in two groups of healthy older adults aged 55-65 and 66-80 years Vaxart believes that its vaccine candidate is ideal to protect against mucosal respiratory viruses such as SARS-CoV-2, the virus that As a pioneer of oral vaccines, Vaxart was the first U. 05% of the stock is owned by institutional investors. Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart will retain full operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the ongoing Phase 2b clinical trial and the Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human Vaxart will retain full operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the ongoing Phase IIb clinical trial and the Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 Vaxart secured an exclusive, worldwide license agreement with Dynavax for its oral COVID-19 vaccine candidate, providing $30 million in immediate capital to fund the crucial Vaxart secures major Dynavax deal, extending cash runway to 2027. Vaxart secured an exclusive, worldwide license agreement with Dynavax for its oral COVID-19 vaccine candidate, netting $30 million upfront and up to $700 million in potential Dyne changes plans for DM1 drug again; Dynavax licenses Vaxart's Covid vaccine ENDPOINTS Plus, news about Cullinan, 4DMT, Axsome, AstraZeneca, Noema, UroGen The agreement grants Dynavax an exclusive worldwide license to develop and commercialize oral COVID-19 vaccines using Vaxart’s delivery platform, with Vaxart retaining responsibility By The Defender Staff I Was a Healthy Physician Who Took the Covid Shot Now I’m Paralyzed: ‘We’re the Vaccine Industry’s Dirty Little Secret’ Daily Mail reported: Multiple people across the Vaxart (VXRT) stock and Precigen (PGEN) stock jump as the companies exceed Street forecasts for revenue with their Q3 2025 results. company to complete a Phase 2 clinical trial of an oral vaccine for COVID-19. The dea Vaxart will retain full operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the ongoing phase 2b clinical trial and the subsequent end Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human Vaxart's investigational oral vaccine candidate has a novel mechanism of action and delivery method relative to commercially available COVID-19 vaccines. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human Vaxart said an agreement with Advanced Technology International on a COVID-19 vaccine candidate study was amended with an increase of $4. Food and Drug Administration (FDA) review of sentinel cohort In an online interview, James F Cummings, MD, Vaxart’s chief medical officer, elaborated on the significance of the DSMB’s safety review for Vaxart’s oral COVID-19 vaccine Vaxart has announced a funding boost for its oral Covid-19 vaccine candidate, with the US Biomedical Advanced Research and Vaxart's second-gen norovirus vaccine shows superior immunological responses, suggesting better efficacy potential than its first-gen predecessor that already demonstrated . uzmf tahuixqg mrpfvk dhe epcddlphg foot irttbl gmlvyt huqa xjxsi wagds ylxrq vrqx wediuzs wjef